← Back to Clinical Trials
Recruiting NCT00488878

NCT00488878 Data Collection for Patients With Low Grade Ovarian or Peritoneal Tumors

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT00488878
Status Recruiting
Phase
Sponsor M.D. Anderson Cancer Center
Condition Low Grade Ovarian Serous Adenocarcinoma
Study Type OBSERVATIONAL
Enrollment 2,000 participants
Start Date 2006-05-19
Primary Completion 2034-05-01

Eligibility & Interventions

Sex Female only
Min Age N/A
Max Age N/A
Study Type OBSERVATIONAL
Interventions
Biospecimen CollectionElectronic Health Record Review

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 2,000 participants in total. It began in 2006-05-19 with a primary completion date of 2034-05-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study collects information to maintain a database on patients with low-grade ovarian or peritoneal tumors. Collecting information about the type of cancer and treatment, as well as details about follow-up care, may help researchers learn and better understand these tumor types and help develop better treatments for them.

Eligibility Criteria

Inclusion Criteria: * Patients whose disease progressed to a higher-grade carcinoma since the time of original diagnosis: * Ovarian tumor of low malignant potential * Low-grade serous carcinoma of the ovary * Primary peritoneal tumor of low malignant potential * Low-grade serous carcinoma of the peritoneum * Psammocarcinoma

Contact & Investigator

Central Contact

Lisa Nathan

✉ lcnathan@mdanderson.org

📞 713-745-3837

Principal Investigator

David M Gershenson

PRINCIPAL INVESTIGATOR

M.D. Anderson Cancer Center

Frequently Asked Questions

Who can join the NCT00488878 clinical trial?

This trial is open to female participants only, studying Low Grade Ovarian Serous Adenocarcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT00488878 currently recruiting?

Yes, NCT00488878 is actively recruiting participants. Contact the research team at lcnathan@mdanderson.org for enrollment information.

Where is the NCT00488878 trial being conducted?

This trial is being conducted at Houston, United States.

Who is sponsoring the NCT00488878 clinical trial?

NCT00488878 is sponsored by M.D. Anderson Cancer Center. The principal investigator is David M Gershenson at M.D. Anderson Cancer Center. The trial plans to enroll 2,000 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology